{"id":"W4407701764","doi":"10.1200/jco.2025.43.5_suppl.808","title":"ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Urothelial cancer; Oncology; Internal medicine; Cancer research; Cancer; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001342202,0.001192158,0.001172189,0.0004135484,0.0004187093,0.001156957,0.0009544747,0.001607847,0.007467652],"category_scores_gemma":[0.0007397682,0.0004758906,0.001248799,0.0004740501,0.0006209982,0.001009241,0.0003637936,0.003795306,0.001439534],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001057734,"about_ca_system_score_gemma":0.00173909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001367349,"about_ca_topic_score_gemma":0.004442772,"domain_scores_codex":[0.9996701,0.0001531881,0.00001906652,0.00004235138,0.00003725809,0.00007797535],"domain_scores_gemma":[0.9995897,0.00006247056,0.00008810475,0.00002911036,0.00002618825,0.0002043634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6879796,0.06991381,0.006254425,0.001917861,0.002465622,0.0004649186,0.0003185192,0.006889076,0.03441679,0.001006912,0.01951668,0.1688556],"study_design_scores_gemma":[0.6144432,0.3621922,0.008659962,0.0001235962,0.0005464035,0.0004783333,0.0000827543,0.002166387,0.003106499,0.0004249101,0.007734396,0.0000413537],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972818,0.004264803,0.001075084,0.00158897,0.0004121396,0.004990546,0.004735573,0.0003449412,0.009769906],"genre_scores_gemma":[0.9720771,0.003436871,0.002750768,0.002750247,0.000224468,0.004289319,0.00583696,0.0000834757,0.008550799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007467652,"threshold_uncertainty_score":0.0249818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07342563517190712,"score_gpt":0.4425989456182562,"score_spread":0.3691733104463492,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}